TCR-Nck Modulators: Pioneering Oral Modulation of T Cell Receptor Activation Holding the Promise of Treating Autoimmune Diseases

Share:

Christopher VanDeusen presented data on the mechanism of action of AX-158, a first-in-class Nck modulator, at ACR Convergence 2024. The mechanism of AX-158 holds broad potential to treat various autoimmune diseases without causing immunosuppression.

Request a copy of the poster

Complete the form below to request a digital copy of the poster.

This field is for validation purposes and should be left unchanged.